The OxyContin maker Purdue Pharma is on the verge of dissolving, following a federal judge's approval of its criminal sentence. This decision clears the way for a massive legal settlement that will resolve thousands of lawsuits and transform the company into a public-benefit entity. Here are the key questions and answers about this pivotal moment in the opioid crisis.
What is happening to Purdue Pharma?
Purdue Pharma, the company that manufactured the addictive painkiller OxyContin, is set to dissolve by the end of the week. Under the terms of a sweeping legal settlement, the original corporation will cease to exist and be replaced by a new entity focused on public health. This transformation comes after years of litigation, including thousands of lawsuits from states, cities, tribes, and individuals blaming Purdue for fueling the opioid epidemic.
Why did the judge approve the criminal sentence?
U.S. District Judge Madeline Cox Arleo presided over the criminal sentencing hearing that was the final hurdle for the settlement. Despite hearing hours of emotional impact statements from families who lost loved ones to addiction and from people struggling with substance use themselves—many of whom urged her to reject the deal—she ultimately approved the negotiated sentence. Judge Arleo acknowledged the profound suffering caused by the epidemic but determined that the settlement, which includes the dissolution of Purdue and billions in compensation, was legally appropriate and in the public interest.
What did victims say during impact statements?
During the hearing, numerous individuals gave powerful impact statements. They shared stories of losing children, siblings, and parents to opioid overdoses, and described their own battles with addiction after being prescribed OxyContin. Many expressed anger that the Sackler family, which owned Purdue, would not face criminal charges, and they argued the settlement let them off too easily. Judge Arleo listened attentively, stating she sympathized deeply with the victims and understood their demands for harsher accountability. However, she maintained that the settlement was the best outcome achievable under the law.
What will replace Purdue Pharma?
In place of the old Purdue Pharma, a new company called Knoa Pharma will emerge. Knoa is structured as a “public benefit corporation,” meaning its mission is to serve the public good rather than maximize profits. It will operate under strict oversight and will channel its revenues into addiction treatment, overdose prevention, and other measures to combat the opioid crisis. All ownership and control by the Sackler family will be eliminated, and the company’s profits will be used to repay creditors and fund abatement programs.
How many deaths are linked to the opioid epidemic?
According to federal data cited in the case, the opioid epidemic has been linked to more than 900,000 deaths in the United States since 1999. This staggering toll includes overdoses from prescription opioids like OxyContin, as well as illicit drugs such as heroin and fentanyl. The epidemic has devastated communities across the country, overwhelming healthcare systems and leaving countless families grieving. Purdue Pharma’s aggressive marketing of OxyContin, which downplayed its addiction risks, played a central role in the early stages of the crisis.
What role did the Department of Justice play?
The Department of Justice (DOJ) conducted a lengthy investigation into Purdue Pharma’s conduct, including allegations that the company misled doctors and patients about OxyContin’s addictive properties. The DOJ’s probe resulted in criminal charges against the company, including fraud and conspiracy. The negotiated criminal sentence—approved by Judge Arleo—is a key component of the overall settlement. As part of the deal, Purdue pleaded guilty to multiple felonies and agreed to pay billions of dollars in fines and forfeitures. The DOJ did not bring criminal charges against individual Sackler family members, a point of contention for many victims.